What is liver transplant rejection and how common is it?

Rejection occurs when the recipient’s immune system recognises the donor liver as foreign and mounts a response against it — a biologically rational process that immunosuppressive medications are designed to override. If drug levels fall too low, or if immune activation is particularly strong, that response breaks through.

There are two categories that matter clinically. Acute cellular rejection (ACR) is T-cell mediated and is by far the more common form. In studies where biopsies are performed based on rising liver tests, the incidence is 10–30%. ACR occurs most often in the first 3 months post-transplant, when immune activation is highest and drug dosing is still being calibrated — though it can also appear years later, particularly when doses have been missed.

Chronic rejection — also termed ductopenic rejection or vanishing bile duct syndrome — develops in fewer than 5% of adult recipients with modern immunosuppression protocols. It usually evolves from repeated or unresolved acute episodes, causing progressive loss of the small bile ducts within the liver. Once ductopenia is established and irreversible, retransplantation may be the only option. That trajectory, from acute to chronic rejection, is the clearest argument for treating the first episode seriously.

What are the warning signs of rejection after a liver transplant?

The most important thing to know about rejection symptoms is that many episodes produce none at all — at least not early. The first sign is often a quiet rise in liver function tests on a routine blood draw, before the patient has noticed anything wrong. That is precisely why the monitoring schedule exists and why it must be kept.

When symptoms do appear, the picture typically includes jaundice (yellowing of the skin or whites of the eyes), right upper abdominal discomfort or a sense of fullness over the liver, low-grade fever — more common in early acute rejection — and fatigue that seems disproportionate to the patient’s stage of recovery. Dark urine and pale stools reflect impaired bile flow and are worth reporting promptly when they occur together.

None of these findings is specific to rejection. Biliary stricture, infection — including CMV and EBV, which are post-transplant concerns in their own right — drug toxicity, and vascular complications can all present with an identical pattern. A rise in liver enzymes in a post-transplant patient is a problem that requires investigation, not a diagnosis in itself. What the problem is determines the treatment, and those treatments differ substantially. The discipline to seek an answer rather than assume one is foundational to good post-transplant care.

How is rejection diagnosed — do you need a biopsy?

Blood tests can raise the suspicion; they cannot confirm the diagnosis. Elevated ALT, raised bilirubin, and a climbing alkaline phosphatase are consistent with rejection but are equally consistent with a biliary complication, a viral infection, or hepatotoxicity from a new medication. Treating empirically — giving steroids without a tissue diagnosis — risks missing a condition that steroids will not fix, or that steroids may actively worsen.

Liver biopsy with histological grading using the Banff criteria is the diagnostic gold standard. The Rejection Activity Index (RAI) evaluates three components: the degree of portal inflammation, the extent of bile duct damage, and the presence of venous endothelial infiltration. Each is scored on a 1–3 scale, producing a cumulative RAI of 3 to 9, which maps to a qualitative verdict of indeterminate, mild, moderate, or severe rejection. Mild acute rejection (RAI 3–4) in a clinically stable patient may be managed with optimisation of tacrolimus rather than pulse steroids; moderate to severe rejection warrants immediate treatment escalation.

Percutaneous liver biopsy is a well-established, low-risk procedure. At centres with transplant expertise, the combination of clinical context, laboratory trends, imaging, and histology produces a precise, actionable diagnosis. Treating a biliary stricture with steroids — or treating rejection with antibiotics — wastes time the graft may not have. See our hepatology and liver transplant services for the full range of diagnostic capabilities at our centre.

What are the treatment options for acute and chronic rejection?

Acute cellular rejection, caught early, is one of the more rewarding problems in transplant hepatology — not because it is trivial, but because it responds well when addressed promptly. High-dose intravenous corticosteroids, typically methylprednisolone given as pulse doses over 3 days, are first-line treatment. Most patients see meaningful improvement in liver tests within 48–72 hours. A repeat biopsy performed 4 weeks later generally confirms resolution of the inflammatory infiltrate and restoration of normal hepatic architecture.

Steroid-resistant rejection — defined as the absence of meaningful liver test improvement within approximately 5 days of completing a steroid pulse — requires escalation. Anti-thymocyte globulin (ATG) is an established second-line option used in this setting, with published series demonstrating response in a significant proportion of cases.

Concurrent with specific anti-rejection treatment, tacrolimus levels are reviewed and adjusted to ensure the trough is within the therapeutic target range. A patient presenting with rejection while underutilising their immunosuppression needs the drug corrected at the same time as the inflammation treated.

Chronic rejection is a harder problem. Established ductopenia does not reliably reverse. When caught at an early, pre-irreversible stage, aggressive optimisation of immunosuppression sometimes halts progression. Advanced chronic rejection with graft failure leaves retransplantation as the only definitive option — and that pathway carries its own complexity in terms of listing priority and donor availability. The argument for early, decisive treatment of acute rejection is partly the argument for never reaching this stage.

How does immunosuppression prevent rejection — and what happens if you miss doses?

Tacrolimus is the cornerstone of maintenance immunosuppression for the vast majority of liver transplant recipients worldwide. It works by inhibiting calcineurin — a protein required for T-cell activation — blocking the immune cascade that would otherwise target the donor liver. The drug’s effect depends entirely on maintaining a consistent blood concentration. Below the therapeutic threshold, immune activation can break through; above it, toxicity becomes the concern, most significantly nephrotoxicity.

This is why trough level monitoring — a blood draw taken at a defined interval before the next dose — is a fixed part of every post-transplant follow-up protocol. According to the 2024 EASL Clinical Practice Guidelines on Liver Transplantation, tacrolimus trough targets are typically 6–10 ng/mL in the first month post-transplant, with lower maintenance targets thereafter as the risk of rejection declines with time.

Non-adherence — missing doses, or taking them at irregular intervals — is among the most common and most preventable causes of late acute rejection and graft loss. It is a particular risk in younger patients and in those several years out from transplant who have felt well for a long time. Feeling well is not evidence that the medication is no longer necessary; it is evidence that the medication is working. A single lapsed day is usually inconsequential. A pattern of missed doses can drive trough levels below the protective floor, sometimes without warning and with consequences that cannot always be undone.

If the cost of tacrolimus, side effect concerns, or difficulty with the twice-daily schedule are creating barriers, raise them with your transplant team. Extended-release formulations, dose timing adjustments, and other practical measures are available — but only if the team knows the problem exists. For more on life after transplant, see our overview of liver transplant care in India, and for international patients, the international patient page has specific guidance on remote follow-up options.

When should you contact your transplant team without delay?

After a liver transplant, there is a defined set of symptoms that require same-day contact with your transplant team — not a wait-and-watch approach, not a message to a GP who does not have your transplant history. Time matters.

Contact your transplant team immediately if you develop jaundice (any yellowing of skin or eyes), fever above 38°C at any point in the first year or persistent fever thereafter, new or significantly worsening fatigue, abdominal pain or swelling over the liver area, dark urine combined with pale stools, or any concern that your blood test results are trending upward before your next scheduled appointment.

The last point is worth emphasising: if you have access to your own results through a patient portal and you notice the numbers moving in the wrong direction, do not wait for your next clinic date. A phone call now is worth far more than a confirmed rejection episode later.

At Gleneagles Hospital Mumbai, the hepatology and liver transplant team provides post-transplant follow-up for both local and international patients. NRI and overseas recipients can access teleconsultation for remote monitoring and assessment — our services page has contact and appointment details.